Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

NCT01372228 is registered in ClinicalTrials.gov with Talaris Therapeutics Inc. as lead sponsor.

NCT NCT01372228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01372228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
Lead sponsor
Talaris Therapeutics Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2011
Completion date
April 30, 2016
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenoleukodystrophy (ald and amn), alpha-mannosidosis, hunter syndrome (mps ii), hurler syndrome (mps i), hurler-scheie syndrome, krabbe disease (globoid leukodystrophy), metachromatic leukodystrophy (mld), niemann-pick disease, pelizaeus merzbacher (pmd), sandhoff disease, sanfilippo syndrome (mps iii), tay sachs disease